Alto Neuroscience (NYSE:ANRO) Downgraded to “Strong Sell” Rating by Zacks Research

Zacks Research downgraded shares of Alto Neuroscience (NYSE:ANRO) from a hold rating to a strong sell rating in a research note published on Wednesday morning,Zacks.com reports.

Other equities analysts have also issued research reports about the stock. Bank of America initiated coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price objective for the company. Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a report on Wednesday, April 22nd. JonesTrading decreased their target price on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Alto Neuroscience in a report on Wednesday, June 17th. Finally, Wall Street Zen upgraded Alto Neuroscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and an average target price of $35.25.

Alto Neuroscience Stock Down 1.5%

NYSE ANRO opened at $26.81 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. The company has a market capitalization of $940.76 million, a P/E ratio of -11.08 and a beta of 1.04. Alto Neuroscience has a one year low of $2.97 and a one year high of $28.85. The stock has a 50 day moving average price of $23.39 and a 200-day moving average price of $21.46.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, equities analysts predict that Alto Neuroscience will post -3.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ANRO. Commodore Capital LP bought a new stake in shares of Alto Neuroscience in the 4th quarter worth about $32,453,000. Perceptive Advisors LLC grew its holdings in Alto Neuroscience by 1,048.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after purchasing an additional 1,629,027 shares during the last quarter. Vestal Point Capital LP grew its holdings in Alto Neuroscience by 161.6% during the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after purchasing an additional 1,535,000 shares during the last quarter. Spruce Street Capital LP raised its position in Alto Neuroscience by 494.7% in the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock worth $29,116,000 after purchasing an additional 1,102,366 shares during the period. Finally, Vivo Capital LLC purchased a new stake in Alto Neuroscience in the 4th quarter worth about $18,433,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.